Dystextia: An Early Sign of Pregnancy-Associated Meningioma

James B. Hannah¹, Phillip Kissel², Bianca Russell³, Jo Ellen Hose⁴

¹Central Coast Pathology Consultants, San Luis Obispo, USA
²Department of Neurosurgery, Sierra Vista Regional Medical Center, San Luis Obispo, USA
³Cincinnati Children’s Hospital, Cincinnati, USA
⁴California Polytechnic State University, San Luis Obispo, USA
Email: jhannah@ccpathology.com

Received 20 February 2014; revised 20 March 2014; accepted 28 March 2014

Abstract

Objective: The authors report a case of meningioma causing incomprehensible and excessive text messaging in a postpartum woman. Case Report: We report the case of expressive dystextia related to a postpartum, progesterone receptor-positive meningioma. Growth of meningiomas can accelerate during pregnancy and the postpartum period due to expression of hormone receptors, particularly progesterone. This is the first study describing dystextia related to a brain tumor; previous cases of dystextia are associated with stroke and complex migraine. Here expressive dystextia, the inability to compose syntactically comprehensible text messages, preceded acute neurologic signs by several months, and surgical resection of the meningioma eliminated all neurologic sequelae. Possible genetic etiologies for meningioma are discussed since this patient’s prior thyroid cancer at age 18 suggests a relationship between the two neoplasms. Conclusions: Since text messaging is becoming one of the principal forms of communication in our society and requires both cognitive and motor skills, clinicians should be aware that dystextia may be the initial sign of significant neurologic pathology. We propose that an inquiry about altered text messaging frequency and comprehensibility should be a standard part of the neurologic evaluation.

Keywords
Meningioma, Brain Tumor, Dystextia, Progesterone Receptor, Text Messaging

1. Introduction

Dystextia, the difficulty or inability to send text messages, has recently been described as a resolvable symptom of ischemic stroke [1]-[3] and complicated migraine [4]. Since texting is a complicated activity involving vision,
language and motor skills, dystextia is expected to become an increasingly common sign of neurologic disease with growing cell phone communications [1] [4]. Neurologic deficits can affect motor skills essential for typing text messages [1] or produce the text messaging equivalent of expressive dysphasia [2]-[4] which we term “expressive dystextia” and define as the loss of ability to compose syntactically comprehensible text messages. To our knowledge, we report the first case of expressive dystextia as an early sign of pregnancy-associated meningioma.

Meningiomas are the most frequently diagnosed primary brain tumor and have been routinely recognized in the context of pregnancy and the postpartum period [5]-[10]. Pregnancy may contribute to rapid expansion of normally slow-growing cerebral meningiomas due to hormone receptor expression [8] [11] [12]. Approximately half of benign intracranial meningiomas are progesterone receptor-positive, and the increase in serum progesterone levels during the second half of pregnancy may fuel growth of these low-grade neoplasms [13] [14]. Meningioma expansion has also been reported with increased progesterone production during the luteal phase of the menstrual cycle and in a male-to-female transsexual patient receiving estrogen-progesterin therapy [8] [15]. In one patient, reduction of multiple meningiomas and complete resolution of one tumor were accomplished by discontinuation of the long-term use of a progesterone agonist [16]. The prevalence of meningiomas found incidentally in older women is at least 1%, and two systematic reviews document a higher meningioma risk for postmenopausal women currently receiving hormone replacement therapy [5] [7] [10] [17]. However, the effect of routine oral contraceptive use on meningioma risk is unclear except for an increased risk of using long-acting hormonal contraceptives [7] [10].

Patients with meningiomas may exhibit evolving subtle language and speech deficits or may present with acute neurological changes in mental status [8] [9] [18] [19]. This case report adds expressive dystextia to the neurologic deficits associated with meningioma. With the worldwide increase in text communication, difficulty in text messaging may become a more widely appreciated sign of incipient neurologic disease [1].

2. Case Report

2.1. History and Presentation

The patient, a 36-year-old right-handed female, was admitted to the emergency room after being found with a depressed level of consciousness and difficulty with arousal. She was 7 months postpartum with a 4-month history of depression, decreasing cognition, and increasing headache. Prior to the birth of her child, she sent text messages to her relatives once or twice weekly. As her depression worsened, the frequency of her text messaging increased to approximately two every hour, day and night, sometimes to people in the next room. Relatives noted progressive incomprehensibility of her text communications during this period. Previous history included surgery for thyroid cancer at age 18 followed by continuous pharmacologic treatment for hypothyroidism but no radiation therapy to head or neck. Informed consent was obtained from the patient for both presentation and publication of her case.

2.2. Treatment

An unenhanced computed tomography (CT) scan of the brain from the emergency room showed a 7.8 cm right frontal mass with acute intratumoral hemorrhage and severe shift of midline (Figure 1). An emergent right frontal craniotomy was performed. The darkened dura was opened, revealing a bluish underlying cerebral cortex and a hematoma spontaneously extruding through the pial layer. Intraoperatively, the lesion was relatively sharply demarcated and was dural-based. The tumor had a pseudocapsule which allowed separation from the surrounding edematous cortex. The dural attachment was localized to the posterior wall of the right frontal sinus. There was no evidence of macroscopic invasion of the pia, pericranium or inner table of the bone. The craniotomy closure was routine but multiple blood products were transfused during the procedure. A post-operative CT scan confirmed gross total resection of the brain tumor with expected, residual right hemispheric swelling (Figure 2). Post-operative management for a benign meningioma with a gross total resection is surveillance. This includes observation for potential neurological decline and a yearly MRI scan with contrast.

2.3. Pathological Findings

Examination of formalin-fixed intraoperative tissue revealed a meningioma, World Health Organization (WHO)
Figure 1. Pre-operative axial (a) and sagittal (b) non-contrast CT scans of large right frontal meningioma (arrows) with hematoma.

Figure 2. Post-operative axial (a) and sagittal (b) noncontrast CT scans of resected right frontal meningioma.

Grade 1. Routine hematoxylin and eosin sections demonstrated a meningothelial neoplasm with areas of clear cell change and loss of whirling architecture (Figure 3). No glial invasion or obvious tumor necrosis were identified, and the specimen exhibited no mitotic figures or cytologic atypia. Results of well-controlled immunohistochemical stains were: glial fibrillary acidic protein (GFAP)-negative, thyroid transcription factor-1 (TTF-1)-negative, and cytokeratin CAM5.2-negative with weak vimentin and strong positive epithelial membrane antigen (EMA) nuclear staining. The Ki-67 proliferative index was approximately 5%. Tumor cells were estrogen receptor-negative and highly positive for progesterone receptors with 95% of the cells exhibiting moderate to strong nuclear staining (Figure 4).

2.4. Outcome
The neurologic assessment on day 2 post-operative revealed mild to moderate attention and short-term memory deficits. Ability to swallow and ambulate improved until her discharge to family on day 4. She had minimal residual expressive dysphasia that resolved, and she normalized her speech function within three weeks. She returned to all normal mental and physical activities by the third post-operative month. Her family reported that she had resumed coherent daily texting activities, and she was not contemplating further pregnancy. A followup MRI at one year post-surgery was normal.

3. Discussion
Expressive dystextia in this patient was coincident with headache and depression, both of which are common in the postpartum period [5] [20] [21]. Although expressive dystextia can be one component of expressive dysphasia, the latter is more often manifest verbally and as difficulty with written language [4]. Detection of dysphasia using text messages is obviously more challenging compared to conventional written composition since texting has fewer restrictions regarding grammar and punctuation [22], but our patient’s text messages lacked syntax common to both written and text communication. Syntactic performance has been localized to the left inferior
frontal gyrus and Brodmann area 45 [23], both of which could have been compressed in our patient due to her large right frontal mass and midline deviation. This expressive dystextia is distinct from the only other reported case of dystextia following left-sided stroke and hemiparesis in a poorly controlled type 2 diabetic that reduced the typing speed and accuracy of his text messages [1]. Following surgical resection of her meningioma, our patient rapidly recovered memory and language skills.

Long-term prognosis for WHO Grade 1 benign meningiomas is positive, particular in view of their expression of progesterone receptors and low mitotic rate [11]-[14] [24]. However, diagnosis of meningioma in our patient 18 years after previous thyroid cancer surgery at age 18 raises the possibility of a genetic link between the two neoplasms. Thyroid carcinoma and meningioma occasionally co-occur or appear as sequelae following radiation or chemotherapy, but this patient was not treated radiologically for her thyroid cancer [25]-[28]. A study of 1228 patients, 50 of whom had previous extracranial malignancies detected an epidemiological link between papillary carcinoma of the thyroid and meningioma [29]. In that series, none of the cancers was related to prior radiation exposure or a known preneoplastic syndrome such as multiple endocrine neoplasia (MEN). However, meningiomas have been added to the list of frequent neoplasms in multiple endocrine neoplasia type 1 linked by their loss of the MEN gene product, a putative tumor suppressor on chromosome 11q [30]. In that study, meningiomas appeared at an average of 18 years following the first neoplasm. However, genetic analysis was not undertaken on this patient.

A genetic etiology for meningioma tumorigenesis centers on chromosome 22q since about half of sporadic meningiomas exhibit monosomy, loss of heterozygosity or partial deletion of chromosome 22 [12]. Loss of expression of NF2 (Merlin) and DAL-1 tumor suppressors on 22q appear to be early events in the neoplastic transformation of meningioma as well as involvement in the pathogenesis of lung and breast cancers, tumors with elevated incidences in families of meningioma patients [28] [31] [32]. Sughrue et al. suggested a possible link between meningioma and thyroid carcinoma through upregulation of somatostatin receptors or through mutations of genes in the B-Raf/Merlin/NF2 pathway [29]. Other genes involved in the initial neoplastic transformation of meningiomas (meningioma gene MN1) may also be located on chromosome 22q. Progression to atypical or malignant meningiomas is associated with loss of progesterone receptor staining, an increased mitotic rate and with abnormalities of other chromosomes including loss of 1p [12] [22]. Such complex karyotypes
are also present in radiation-associated meningiomas [12] [22]. Tumoral edema and angiogenesis, such as observed in our patient’s meningioma, has been linked to production of vascular endothelial growth factor (VEGF) [12].

First-degree family history of meningioma increases relative risk for meningioma in younger patients by 5.4 times [28]. Family history of cervical, breast and lung cancer is also associated with meningioma, as is a personal history of uterine fibroid tumors, endometriosis and possibly breast cancer [28]. Since the presence of an early thyroid carcinoma in this meningioma patient is consistent with a genetic etiology, further genetic analysis could aid the elucidation of the molecular etiology of these benign progesterone receptor-positive neoplasms as well as provide guidance regarding surveillance for her and affected family members.

4. Conclusion

We present a postpartum patient with a progesterone-receptor-positive meningioma who developed increasing depression, headache and incomprehensible text messages (expressive dystextia). These symptoms were reversed following surgical resection of the meningioma. The expressive dystextia described in this case relates to loss of written syntactical skills and is distinct from other reported cases of dystextia that involve loss of motor skills following ischemic stroke. We speculate that this patient’s meningioma may have a genetic basis since she also had a previous thyroid cancer, and these two cancers can share common genetic etiologies. Since text messaging is becoming one of the principal forms of communication in our society and requires both cognitive and motor skills, clinicians should be aware that dystextia may be the initial sign of significant neurologic pathology. We propose that an inquiry about altered text messaging frequency and comprehensibility should be a standard part of the neurologic evaluation.

References


List of Abbreviations

B-Raf: Serine/Threonine Protein Kinase-B-Raf
CAM5.2: Anti-Low Molecular Weight Cytokeratin Antibody
CT: Computed Tomography
DAL-1: Erythrocyte Membrane Protein Band 4.1-Like 3 Gene
EMA: Epithelial Membrane Antigen
GFAP: Glial Fibrillary Acidic Protein
Ki-67: Antigen KI-67
MEN: Multiple Endocrine Neoplasia Gene
MN1: Meningioma (Disrupted in Balanced Translocation 1) Gene
MRI: Magnetic Resonance Imaging
NF2: Neurofibromatosis 2 Tumor Suppressor Gene
TTF-1: Thyroid Transcription Factor-1
VEGF: Vascular Endothelial Growth Factor
WHO: World Health Organization